Syros Pharmaceuticals sells Tamibarotene assets to Rege Nephro

Rege Nephro has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals (SYRS), through a mutual agreement. The acquisition was completed on February 26. This acquisition, encompassing their clinical and non-clinical data including human safety study for new drug application, contracts with a contract manufacturing organization, and Tamibarotene active pharmaceutical ingredient and drug products, is expected to enhance Rege Nephro’s capabilities and streamline operations for its clinical trial operations in the United States.